[
14 C]palmitate (Perkin Elmer) as previously described (12) . Activation of AMPK in vivo was assessed after intraperitoneal injection of salicylate (250 mg/kg) or A-769662 (30 mg/kg) in β1-KO or WT mice.
These doses are comparable to those used in previous studies that have observed improvements in insulin sensitivity following chronic treatment in obese rodent models (120 mg/kg salicylate by continuous infusion (14) ; 30 mg/kg intraperitoneal A-769662 (15) . Tissues were harvested (16) after 90 min and stored at -80°C until analysis. Analysis of respiratory exchange ratio was performed using the Oxymax Columbus Instruments Comprehensive Lab Animal Monitoring System; mice were acclimatized to the system for 24 hr prior to data collection. β1-KO and WT mice were fasted overnight and allowed access to food at 07:00. After a re-feeding period, mice were injected with salicylate (250 mg/kg), A-769662 (30 mg/kg) or vehicle (saline for salicylate, 5% dimethyl sulfoxide in phosphate-buffered saline for A-769662) at 09:00. After injection, mice were denied access to food, and respiratory measurements were continued until 19:00. The same cohort was used for all treatments, with one week separating salicylate and A-769662 injections. Rates of carbohydrate (4.58*VCO 2 -3.23*VO 2 ) and fat (1.70*VO 2 -1.69*VCO 2 ) utilization were calculated as previously described (17) .
Analyses of in vivo phosphorylation and expression of AMPK and ACC, and serum non-esterified fatty acids (NEFAs), were performed as described (4).
Cell culture
HEK-293 cells stably expressing WT or R531G mutant γ2 have been described (1) . HEK-293 cells expressing FLAG-tagged human β1 (WT or S108A mutant) or WT β2 from a tetracycline-inducible promoter were made using the Flp-In™ system (Invitrogen) according to manufacturers' protocols.
HEK-293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/L glucose, 10% (v/v) foetal bovine serum, 100 IU/ml penicillin, 100 μg/ml streptomycin and 200 μg/ml hygromycin B. Expression of β1/β2 subunit was induced, 24 hr prior to treatment, by addition of 1 µg/ml tetracycline (Invitrogen). After various treatments as indicated in figure legends, cells were lysed using the rapid lysis procedure (2) and lysates stored at -80 o C until use.
Kinase and phosphatase assays
AMPK was assayed using the SAMS peptide ( Figs. 2A-E) or AMARA peptide (all other Figures) as previously described (2, 18) , substrate except that assays were at 2 mM rather than 200 µM ATP. In pilot experiments performed at the sub-physiological ATP concentration of 200 µM, we found that although salicylate activated AMPK at concentrations of 0.3 -3 mM, at concentrations above 3 mM it began to inhibit (not shown). The inhibitory effect could be eliminated by carrying out the assays at 2 mM ATP ( Fig. 2A) , suggesting that it was due to competition between salicylate and ATP at the catalytic site on AMPK. AMPK from cell lysates (60 μg protein) was assayed in immunoprecipitates made using anti-α1/α2 antibodies or EZview Red anti-FLAG M2 affinity gel (Sigma) as specified.
PP2Cα was assayed using a generic kinase peptide substrate (19) after phosphorylation using PKA. S1 ) and the release of 32 P measured.
Analysis of dephosphorylation of AMPK in cell-free assays
Bacterially expressed human AMPK (either α1β1γ1, α1β1[S108A]γ1 or α1β2γ1) was incubated with protein PP2Cα (200 ng) ± 5 mM MgCl 2 , along with either AMP, A-769662 or salicylate as indicated.
After 10 min pT172 phosphorylation was determined by Western blotting, and samples were also diluted 75-fold into AMPK assays to determine kinase activity.
SDS-PAGE and Western blotting
SDS/PAGE was performed using precast Bis-Tris 4%-12% gradient polyacrylamide gels in the MOPS buffer system (Invitrogen). Proteins were transferred to nitrocellulose membranes (Bio-Rad) using the Xcell II Blot Module (Invitrogen). Membranes were blocked for 1 hr in Odyssey blocking buffer (LiCor Biosciences, Cambridge, UK). The membranes were probed with appropriate antibody (0.1-1 µg/ml) in Odyssey blocking buffer. Detection was performed using secondary antibody (0.2 µg/ml) coupled to IR 680 or IR 800 dye and the membranes scanned using the Li-Cor Odyssey IR imager.
Protein concentrations were determined by Coomassie Blue binding (20) with bovine serum albumin as standard.
Other analytical procedures
ADP/ATP ratios and cellular O 2 uptake were measured as described previously (1).
Presentation of data and tests for statistical significance
Where error bars are not visible in X-Y plots, they are smaller than the symbol used to represent the data point. Assays of effects in cultured HEK-293 cells were of replicate dishes of cells, with each value being the mean of duplicate immunoprecipitate kinase assays. Statistical significances of differences were assessed using GraphPad Prism 5 for Mac OSX, with the specific tests used being given in Figure legends . were determined using immunoprecipitate kinase assays (2) and results expressed as mean ± SEM (n = 6 or 7). Statistical significance of differences from controls without salicylate was assessed using two-tailed t tests: ***p<0.001. Duplicate Western blots of equal protein loadings from two animals are shown at the bottom. Note that the α1 and α2
Legends to Supplementary Figures
subunit isoforms of AMPK in mice differ in mass (64 and 62 kDa respectively) and can be resolved by SDS-PAGE; soleus muscle expresses both isoforms whereas adipose tissue expresses mainly α1. homogeneous model assessment-insulin resistance (HOMA-IR) calculated as described (3, 4) . Results are mean ± SEM, n = 5 to 7; significance of differences was determined by 1-way ANOVA, with Bonferroni's test comparing drug treatment with control for each genotype (*p<0.05, **p<0.01, ***p<0.001). After salicylate treatment, whole-body and epididymal fat pad weights were 44.2 ± 1.6/45.8 ± 1.7, and 2.53 ± 0.16/2.78 ± 0.10 (mean ± SEM in gram, WT/β1-KO mice respectively). These differences were not significant by t test.
